2 unknown, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 2, Terminated 1 |
Follow MD1003 100mg capsule: new trials by email Literature Review of MD1003 100mg capsule trials Research Report on MD1003 100mg capsule
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) MD1003 100mg capsule, PLACEBO - Multiple Sclerosis | Phase 3 | Terminated | MedDay Pharmaceuticals SA | 642 | 2016-12-01 | 2020-11-23 |
| Effect of MD1003 in Spinal Progressive Multiple Sclerosis MD1003 100mg capsule, Placebo - Multiple Sclerosis | Phase 3 | Unknown | MedDay Pharmaceuticals SA | 144 | 2013-10-01 | 2017-03-27 |
| Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis MD1003 100mg capsule - Multiple Sclerosis | Phase 3 | Unknown | MedDay Pharmaceuticals SA | 105 | 2013-10-01 | 2017-03-27 |
Multiple Sclerosis (3) · Multiple Sclerosis, Chronic Progressive (2) · Multiple Sclerosis, Relapsing-Remitting (1) · Optic Neuritis (1) · Vision Disorders (1)
France (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Czechia (1) · Germany (1) · Hungary (1) · Italy (1) · Poland (1) · Spain (1) · Sweden (1) · Turkey (Türkiye) (1) · United States (1)
Ayman Tourbah, MD, PhD (2) · Frederic Sedel, MD, PhD (2) · Bruce Cree, MD, PHD (1) · Frederic Sedel, MD, PHD (1)